THE PAIR AND EACH PART
The Pair Has Less Proof Than Either Drug Alone
CJC-1295 changed blood tests. Ipamorelin failed its main human test. The set pair hasn't been tried in a fair study.
Start with three very different levels of proof
Researchers made the two peptides, small protein strings, to affect growth hormone in different ways. This page sets the fixed CJC-1295 / Ipamorelin pair beside CJC-1295 and Ipamorelin alone. You can see who was tested, how long each drug stayed in blood, and the biggest gap for your choice.
CJC-1295 has human blood tests showing growth hormone and IGF-1 stayed high for days [3]. IGF-1 was measured on its own as the growth protein made by the liver. Ipamorelin has one Phase 2 trial—an early human test for benefit and short-term harm—and it missed the main goal [14]. The fixed pair has no fair trial. None is approved medicine, and no human dose or plan appears here.
The tests and gaps sit side by side
| What to compare | CJC-1295 / Ipamorelin | CJC-1295 | Ipamorelin |
|---|---|---|---|
| What it is | Two protein strings. One lasts days; the other starts a short hormone burst. | A copy of the brain's growth-hormone message. DAC has a blood-protein hook; no-DAC doesn't. | A five-piece protein string copying part of the hunger-hormone message. |
| Where most work was done | Cells in a dish and healthy men got both messages. A related drug had human fat trials [1][5][7]. | Adult blood tests measured growth hormone, IGF-1, and other proteins [3][10][11]. | Rats were tested for bone growth, people after bowel surgery, and ferrets for drug-linked weight loss [6][14][16]. |
| Human proof | The drugs were studied apart. The fixed pair has no fair human trial [2][5]. | CJC-1295 blood tests used healthy adults. Rats showed how DAC grips albumin, a blood protein [3][4]. | There was 1 small human blood study and 1 Phase 2 trial, an early check, that failed its main test [14][15]. |
| Time in blood | Half of DAC left in 5.8 to 8.1 days. Half of Ipamorelin left in about 2 hours [3][15]. | Half of DAC left in 5.8 to 8.1 days. Growth hormone stayed high at least 6 days, and IGF-1 at least 9 days [3]. | Half left in about 2 hours. The hormone burst was highest near 40 minutes. No human blood test used a shot under the skin [15]. |
| Drug and sport rules | Not approved. WADA, the world sport-testing body, bans both under its S2 growth-hormone rule. Both left Category 2, FDA's temporary pharmacy list, after a 2024 review; that wasn't approval. | Not approved. WADA bans it under S2. The federal 503A list, for raw ingredients local pharmacies may mix, didn't include it [9]. | Not approved after Phase 2 failed. WADA bans it under S2. It left 503A Category 2 after the Oct 2024 review; that wasn't approval. |
| Main concern | No fair trial tested the blend. Its parts leave blood at different speeds [2][3][15]. | People may confuse DAC with no-DAC. IGF-1 stays high for days, while long safety work is thin [2][3]. | Phase 2 failed. A related drug harmed rat hearts, and long human safety work doesn't exist [13][14]. |
Each drug copies a different hormone message
All three choices affect growth hormone, but not in the same way. CJC-1295 copies the brain's usual message to the growth gland [8]. Ipamorelin copies part of ghrelin, the hormone that helps bring on hunger, and growth-gland cells can read that message [6].
When both messages arrive, the gland can release a larger growth-hormone burst. IGF-1 may rise later [5][7]. That finding explains why the drugs are paired. It doesn't prove the pair improves your health.
The findings came from different test groups
The fixed CJC-1295 and Ipamorelin pair rests on a two-message idea. That idea came from tests with dish-grown cells, healthy men, and people given a related peptide [1][5][7]. CJC-1295 papers mainly asked how high growth hormone and IGF-1 rose and how long they stayed up [3][11].
Ipamorelin first stood out in animal hormone tests [6]. One human trial involved people after bowel surgery. A newer animal test used ferrets losing weight after a cancer drug [12][14]. Keeping those groups separate helps you see which claims truly reached people and which may not fit your health.
Blood changes aren't the same as feeling better
CJC-1295 has the clearest human blood work of the three. In healthy adults, growth hormone and IGF-1 stayed high for days. Another test in young men found changes in several blood proteins [3][10][11]. None asked whether people felt better.
Ipamorelin has the only published Phase 2 human trial here, an early check for benefit and short-term harm. The 114 adults had bowel surgery, and the drug missed its main test [14]. The fixed pair has no fair human trial. Its case comes from the separate drugs and cells in a dish given both messages [5].
So CJC-1295 changed blood tests. Ipamorelin didn't prove a gain in its one larger trial. The pair is discussed most but tested least.
One part lasts days while the other lasts hours
CJC-1295 with DAC stays much longer than Ipamorelin. In people, half the DAC form left in 5.8 to 8.1 days. Growth hormone stayed high for 6 or more days, and IGF-1 stayed high for 9 to 11 days or more [3].
After Ipamorelin entered a vein, half left in about 2 hours. Growth hormone was highest near 40 minutes [15]. Half the no-DAC form of CJC-1295 leaves in about 30 minutes, making that form much shorter than DAC.
A days-long effect and a 2-hour effect may not line up as expected. No fair trial has tested a set timing plan for the pair. Plans shared by users are reports, not findings from a trial that compared them [2]. They don't give you a proven schedule.
Drug agencies haven't approved any of the three
FDA and EMA are major drug agencies; EMA is the main agency across the continent. Neither has approved these three as medicine for people. WADA, the world sport drug-testing body, bans all three under Section S2, its growth-hormone rule.
FDA placed CJC-1295 and Ipamorelin acetate on a temporary 503A Category 2 list in September 2023. That was a waiting list for raw ingredients proposed for pharmacy mixing, not an approval. Both left Category 2 in September 2024 after their backers withdrew the request. On October 29, 2024, a group that advises FDA about pharmacy mixing reviewed both. It didn't back either drug for the final 503A list [9]. Research versions aren't approved drugs.
Each choice leaves a different warning unanswered
For the fixed pair, no fair trial has tested the blend. Its two parts leave blood at very different speeds, so the full growth-hormone rise isn't known for any set plan [2][3][15].
For CJC-1295, IGF-1 stays high for days. Long safety tests don't exist. User reports also mix up DAC with no-DAC, though those forms act quite differently [2][3].
For Ipamorelin, its Phase 2 trial—an early human test—failed [14]. A 28-day study of a related drug found more heart-muscle harm in rats as the amount rose [13]. Ipamorelin wasn't that drug, and no long study has cleared the worry.
When I line up the three, proof weakens as claims move from one drug to the pair. Only the longer drug clearly changed blood readings. No sound proof shows a long plan with the pair improves your health.